The prevalence of bile acid malabsorption in irritable bowel syndrome and the effect of cholestyramine: An uncontrolled open multicentre study

G. Galatola, R. Ferraris, R. Pellerito, A. Barlotta, O. M. Umberto, T. G. Sciaretta, A. Furno, M. Mazzoni, O. Maggiore, G. Ferfoglia, C. Sategna-Guidetti, G. Castellano, A. Corso, E. Fesce, L. Snider, O. S. Anna

Research output: Contribution to journalArticle

Abstract

Objective: To assess the prevalence of bile acid malabsorption and the efficacy of cholestyramine therapy in improving symptoms associated with this condition in patients with diarrhoric type irritable bowel syndrome. Design: Multicentre uncontrolled open prospective trial. Methods: The 7th day abdominal retention of the γ-labelled bile acid selena-homocholic acid taurine (SeHCAT) was measured in 98 patients diagnosed as suffering from irritable bowel syndrome after exclusion of organic disease. Cholestyramine was prescribed to all patients with altered SeHCAT test using a stepwise increasing dose schedule starting from 2g per day until reaching efficacy or 12g per day. Results: The overall prevalence of altered SeHCAT retention was 57.1%; in patients with faecal wet weight of more than 200 g per day the prevalence was 83%, whereas in those with faecal wet weight less than or equal to 200g per day it was 40%. There was an association between increased faecal weight and SeHCAT retention (odds ratio = 6.7, P

Original languageEnglish
Pages (from-to)533-537
Number of pages5
JournalEuropean Journal of Gastroenterology and Hepatology
Volume4
Issue number7
Publication statusPublished - 1992

Fingerprint

Cholestyramine Resin
Irritable Bowel Syndrome
Taurine
Bile Acids and Salts
Multicenter Studies
Acids
Weights and Measures
Appointments and Schedules
Odds Ratio

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Galatola, G., Ferraris, R., Pellerito, R., Barlotta, A., Umberto, O. M., Sciaretta, T. G., ... Anna, O. S. (1992). The prevalence of bile acid malabsorption in irritable bowel syndrome and the effect of cholestyramine: An uncontrolled open multicentre study. European Journal of Gastroenterology and Hepatology, 4(7), 533-537.

The prevalence of bile acid malabsorption in irritable bowel syndrome and the effect of cholestyramine : An uncontrolled open multicentre study. / Galatola, G.; Ferraris, R.; Pellerito, R.; Barlotta, A.; Umberto, O. M.; Sciaretta, T. G.; Furno, A.; Mazzoni, M.; Maggiore, O.; Ferfoglia, G.; Sategna-Guidetti, C.; Castellano, G.; Corso, A.; Fesce, E.; Snider, L.; Anna, O. S.

In: European Journal of Gastroenterology and Hepatology, Vol. 4, No. 7, 1992, p. 533-537.

Research output: Contribution to journalArticle

Galatola, G, Ferraris, R, Pellerito, R, Barlotta, A, Umberto, OM, Sciaretta, TG, Furno, A, Mazzoni, M, Maggiore, O, Ferfoglia, G, Sategna-Guidetti, C, Castellano, G, Corso, A, Fesce, E, Snider, L & Anna, OS 1992, 'The prevalence of bile acid malabsorption in irritable bowel syndrome and the effect of cholestyramine: An uncontrolled open multicentre study', European Journal of Gastroenterology and Hepatology, vol. 4, no. 7, pp. 533-537.
Galatola, G. ; Ferraris, R. ; Pellerito, R. ; Barlotta, A. ; Umberto, O. M. ; Sciaretta, T. G. ; Furno, A. ; Mazzoni, M. ; Maggiore, O. ; Ferfoglia, G. ; Sategna-Guidetti, C. ; Castellano, G. ; Corso, A. ; Fesce, E. ; Snider, L. ; Anna, O. S. / The prevalence of bile acid malabsorption in irritable bowel syndrome and the effect of cholestyramine : An uncontrolled open multicentre study. In: European Journal of Gastroenterology and Hepatology. 1992 ; Vol. 4, No. 7. pp. 533-537.
@article{554d2100db764580aa77d48850c71d9c,
title = "The prevalence of bile acid malabsorption in irritable bowel syndrome and the effect of cholestyramine: An uncontrolled open multicentre study",
abstract = "Objective: To assess the prevalence of bile acid malabsorption and the efficacy of cholestyramine therapy in improving symptoms associated with this condition in patients with diarrhoric type irritable bowel syndrome. Design: Multicentre uncontrolled open prospective trial. Methods: The 7th day abdominal retention of the γ-labelled bile acid selena-homocholic acid taurine (SeHCAT) was measured in 98 patients diagnosed as suffering from irritable bowel syndrome after exclusion of organic disease. Cholestyramine was prescribed to all patients with altered SeHCAT test using a stepwise increasing dose schedule starting from 2g per day until reaching efficacy or 12g per day. Results: The overall prevalence of altered SeHCAT retention was 57.1{\%}; in patients with faecal wet weight of more than 200 g per day the prevalence was 83{\%}, whereas in those with faecal wet weight less than or equal to 200g per day it was 40{\%}. There was an association between increased faecal weight and SeHCAT retention (odds ratio = 6.7, P",
author = "G. Galatola and R. Ferraris and R. Pellerito and A. Barlotta and Umberto, {O. M.} and Sciaretta, {T. G.} and A. Furno and M. Mazzoni and O. Maggiore and G. Ferfoglia and C. Sategna-Guidetti and G. Castellano and A. Corso and E. Fesce and L. Snider and Anna, {O. S.}",
year = "1992",
language = "English",
volume = "4",
pages = "533--537",
journal = "European Journal of Gastroenterology and Hepatology",
issn = "0954-691X",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - The prevalence of bile acid malabsorption in irritable bowel syndrome and the effect of cholestyramine

T2 - An uncontrolled open multicentre study

AU - Galatola, G.

AU - Ferraris, R.

AU - Pellerito, R.

AU - Barlotta, A.

AU - Umberto, O. M.

AU - Sciaretta, T. G.

AU - Furno, A.

AU - Mazzoni, M.

AU - Maggiore, O.

AU - Ferfoglia, G.

AU - Sategna-Guidetti, C.

AU - Castellano, G.

AU - Corso, A.

AU - Fesce, E.

AU - Snider, L.

AU - Anna, O. S.

PY - 1992

Y1 - 1992

N2 - Objective: To assess the prevalence of bile acid malabsorption and the efficacy of cholestyramine therapy in improving symptoms associated with this condition in patients with diarrhoric type irritable bowel syndrome. Design: Multicentre uncontrolled open prospective trial. Methods: The 7th day abdominal retention of the γ-labelled bile acid selena-homocholic acid taurine (SeHCAT) was measured in 98 patients diagnosed as suffering from irritable bowel syndrome after exclusion of organic disease. Cholestyramine was prescribed to all patients with altered SeHCAT test using a stepwise increasing dose schedule starting from 2g per day until reaching efficacy or 12g per day. Results: The overall prevalence of altered SeHCAT retention was 57.1%; in patients with faecal wet weight of more than 200 g per day the prevalence was 83%, whereas in those with faecal wet weight less than or equal to 200g per day it was 40%. There was an association between increased faecal weight and SeHCAT retention (odds ratio = 6.7, P

AB - Objective: To assess the prevalence of bile acid malabsorption and the efficacy of cholestyramine therapy in improving symptoms associated with this condition in patients with diarrhoric type irritable bowel syndrome. Design: Multicentre uncontrolled open prospective trial. Methods: The 7th day abdominal retention of the γ-labelled bile acid selena-homocholic acid taurine (SeHCAT) was measured in 98 patients diagnosed as suffering from irritable bowel syndrome after exclusion of organic disease. Cholestyramine was prescribed to all patients with altered SeHCAT test using a stepwise increasing dose schedule starting from 2g per day until reaching efficacy or 12g per day. Results: The overall prevalence of altered SeHCAT retention was 57.1%; in patients with faecal wet weight of more than 200 g per day the prevalence was 83%, whereas in those with faecal wet weight less than or equal to 200g per day it was 40%. There was an association between increased faecal weight and SeHCAT retention (odds ratio = 6.7, P

UR - http://www.scopus.com/inward/record.url?scp=0026704832&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026704832&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0026704832

VL - 4

SP - 533

EP - 537

JO - European Journal of Gastroenterology and Hepatology

JF - European Journal of Gastroenterology and Hepatology

SN - 0954-691X

IS - 7

ER -